Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPE Ampio Pharmaceuticals	$0.00	$0.01	$0.00 ▼ $0.13	$3K	4.69	713 shs	2,655 shs
CALA Calithera Biosciences	$0.00	$0.00	$0.00 ▼ $0.05	$1K	-2.77	9,860 shs	734 shs
CLVR Clever Leaves	$0.00	$0.00	$0.00 ▼ $1.00	$1K	3531.01	1,479 shs	283 shs
PXMD PaxMedica	$0.00	$0.00	$0.00 ▼ $0.26	$2K	-0.99	11,822 shs	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPE Ampio Pharmaceuticals	0.00%	0.00%	-3.57%	-10.00%	+3.85%
CALA Calithera Biosciences	0.00%	-80.00%	+100.00%	-66.67%	-98.40%
CLVR Clever Leaves	0.00%	0.00%	0.00%	-25.00%	-99.00%
PXMD PaxMedica	0.00%	0.00%	+100.00%	+100.00%	-99.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPE Ampio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CALA Calithera Biosciences	0.6131 of 5 stars	0.0	1.0	0.0	4.5	0.6	0.0	0.0
CLVR Clever Leaves	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PXMD PaxMedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPE Ampio Pharmaceuticals	N/A	N/A	N/A
CALA Calithera Biosciences	N/A	N/A	N/A
CLVR Clever Leaves	N/A	N/A	N/A
PXMD PaxMedica	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPE Ampio Pharmaceuticals	N/A	N/A	N/A	N/A	$4.04 per share	N/A
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
CLVR Clever Leaves	$17.42M	0.00	N/A	N/A	$14.02 per share	0.00
PXMD PaxMedica	N/A	N/A	N/A	N/A	$0.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPE Ampio Pharmaceuticals	-$8.63M	-$11.01	N/A	∞	N/A	N/A	N/A	N/A	N/A
CALA Calithera Biosciences	-$39.65M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CLVR Clever Leaves	-$17.90M	-$11.31	N/A	∞	N/A	N/A	N/A	N/A	N/A
PXMD PaxMedica	-$18.29M	N/A	0.00	∞	N/A	N/A	-3,167.89%	-560.35%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPE Ampio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A
CLVR Clever Leaves	N/A	N/A	N/A	N/A	N/A
PXMD PaxMedica	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPE Ampio Pharmaceuticals	N/A	N/A	N/A
CALA Calithera Biosciences	N/A	N/A	N/A
CLVR Clever Leaves	N/A	N/A	N/A
PXMD PaxMedica	N/A	0.38	0.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPE Ampio Pharmaceuticals	5.73%
CALA Calithera Biosciences	N/A
CLVR Clever Leaves	6.92%
PXMD PaxMedica	4.90%

Insider Ownership

Company	Insider Ownership
AMPE Ampio Pharmaceuticals	3.30%
CALA Calithera Biosciences	6.60%
CLVR Clever Leaves	8.20%
PXMD PaxMedica	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPE Ampio Pharmaceuticals	20	1.14 million	1.10 million	No Data
CALA Calithera Biosciences	60	4.87 million	4.55 million	Not Optionable
CLVR Clever Leaves	560	1.76 million	1.61 million	No Data
PXMD PaxMedica	2	11.31 million	11.20 million	Not Optionable

CLVR, AMPE, PXMD, and CALA Headlines

Recent News About These Companies

PaxMedica, Inc. (PXMD) - Yahoo Finance

July 11, 2025 | nz.finance.yahoo.com

PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions

January 14, 2025 | accesswire.comA

Study Links Iron Deficiency to Disturbed Sleep Among Autism, ADHD Patients

September 23, 2024 | msn.com

BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K

September 3, 2024 | msn.com

PaxMedica Secures Immediate Exercise of Warrants

September 3, 2024 | accesswire.comA

Yale Study Unravels Autism, Brain Growth Patterns

September 1, 2024 | msn.com

PaxMedica, Inc.: PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection

August 27, 2024 | finanznachrichten.de

PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection

August 27, 2024 | accesswire.comA

PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101

May 15, 2024 | globenewswire.com

PXMD Stock Earnings: PaxMedica Misses EPS for Q1 2024

May 13, 2024 | investorplace.com

PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy

May 7, 2024 | markets.businessinsider.com

PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy

May 7, 2024 | finance.yahoo.com

PaxMedica (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA

May 3, 2024 | theglobeandmail.com

PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast

April 26, 2024 | finance.yahoo.com

Urgent Action: PaxMedica (NASDAQ: PXMD) Addresses Medical Crisis in Malawi

April 25, 2024 | theglobeandmail.com

PaxMedica (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA

April 25, 2024 | theglobeandmail.com

PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101

April 23, 2024 | globenewswire.com

PaxMedica, Inc.: PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

April 18, 2024 | finanznachrichten.de

Choosing Unknown Penny Stocks, 3 Top Tips

April 15, 2024 | pennystocks.comP

PaxMedica, Inc.: PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

April 12, 2024 | finanznachrichten.de

New MarketBeat Followers Over Time

CLVR, AMPE, PXMD, and CALA Company Descriptions

Ampio Pharmaceuticals NYSE:AMPE

$0.0027 0.00 (0.00%)

As of 08/22/2025 01:48 PM Eastern

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Calithera Biosciences NASDAQ:CALA

$0.0002 0.00 (0.00%)

As of 08/22/2025 01:38 PM Eastern

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Clever Leaves NASDAQ:CLVR

$0.0003 0.00 (0.00%)

As of 08/22/2025 03:47 PM Eastern

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.

PaxMedica NASDAQ:PXMD

$0.0002 0.00 (0.00%)

As of 08/22/2025

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time